Abstract Anttsense ohgodeoxynucleotrdes have been designed to mhtbrt the productton of spectfic proteins In models of hypertension, we have targeted the renm-angiotensm system at the level of syntheses (angtotensmogen) and the receptor (AT, receptor) The design of annsense ohgonucleottdes requrres choosing a site to mhtbrt mRNA processing or translation The strategy we use is to make three ohgonucleottdes of antisense sequences, upstream and downstream from the AUG site and over the AUG site The ohgonucleotrdes are tested tn a screening test Antrsense ohgonucleondes to AT,-receptor mRNA and to angiotensmogen mRNA reduce blood pressure in spontaneously hypertensive rats when injected into the brain. They srgmficantly reduce the concentratton of the appropriate protein The ohgonucleotrdes are also effective when admtmstered systemically The decrease m blood pressure with anttsense ohgonucleotrdes dehvered tn blood or brain lasts 3 to 7 days To prolong the actton, drrect mJectron of naked DNA and inJectron of DNA In hposome carriers have been tested. Viral vectors have been developed to deliver antisense DNA The viral vectors available mclude retroviruses and adenovrrus, but the adeno-assoctated virus (AAV) vector 1s the vector of chorce for ulttmate use in gene therapy It offers safety because rt is nonpathogenrc, has longevity because rt integrates into the genome, and has sufficient carrying capacity to carry up to 4 5 kb antrsense or gene m a recombinant AAV Using rAAV-anttsense to AT, mRNA, there IS efficrent transfectton into cells and an mhibttion of AT, receptor number In m viva tests, rAAV-AS AT,-receptor when injected into the brains of SHR reduces blood pressure for more than 2 months In young rats (3 weeks old), rAAV-AS AT,-receptor decreases blood pressure and slows the development of hypertension While further experiments need to be done on dose-response relatronships and on the cellular mechantsms of these effects, the results show the feastbthty of AAV as a vector for antrsense mhtbrtion, whtch may ultimately be used tn gene therapy for hypertension (Hypertension. 1997;29[part 21:177-X37.) Key Words l anttsense ohgonucleottde l adeno-associated vtral vector l AT, receptor l angtotensm H ypertension 1s one of the most important risk factors for myocardial mfarctton, stroke, congestive heart failure, end-stage renal disease, and peripheral vascular disease la2 Twenty-four percent (an estimated 43 million) of the adult, ctvtlran, nomnstttutionaltzed populatton of the United States has hypertension.3 The Incidence of hypertension 1s slightly more prevalent among men than women. Many drugs are avatlable for hypertension control, including new drugs that inhibit the Ang receptor or mhibit calcmm channels. All present drug regimens suffer from one obvious disadvantage. Since the disease of hypertension 1s ltfelong, treatments have to be repeated daily. In the case of drug treatment, compliance wrth a dally ratron of pills by the patients is difficult to mamtam Our goal in developing a gene therapy approach to hypertension is to find effective ways of modtfymg genes chronically in vrvo We have used antrsense sequences and delivery systems that allow a single dose of a specific gene antimessage to have prolonged effects over several days, weeks, or months Although hypertension is a polygenic dtsease, single genes may play significant roles that can be modified by gene regulatron Lifton has contributed greatly to tdenttfymg rare examples of single-gene causes of hypertension and isolated various defects m the fundamental celFrom the
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The apparent increased activity of Ang m bram tissue of SHR gave us a starting point for testing the effectiveness of antisense inhibition m lowering blood pressure m hypertensive animals. Earlier experiments11 had shown that a single injection of the nonspectfic Ang antagonist Sar'Ile8Ang II injected mto the brain produced a brief but Selected Abbreviations and Acronyms AAV = adeno-associated virus AAV-AS = adeno-associated virus-antisense Ang = angiotensm AS-ODN = antisense ohgodeoxynucleotlde AT = angiotensm type II AVP = argmme vasopressm CMV = cytomegalovirus ITR = Inverted termmal repeat LTR = long-termmal repeat ODN = ohgodeoxynucleotide paAo = plasrmd for angiotensmogen antisense paAT, = plasnud for AT,-receptor antisense PCR = polymerase cham reaction rAAV = recombinant adeno-associated virus rAAV-AS = recombinant adeno-associated virus-antisense RAS = remn-anglotensm system RT-PCR = reverse transcription-polymerase chain reaction SHR = spontaneously hypertensive rats TGF = transforming growth factor TRH = thyrotropm-releasing hormone VSMC = vascular smooth muscle cell WKY = Wistar Kyoto rats wtAAV = wild-type adeno-associated virus significant decrease m blood pressure at a dose that was ineffective when given peripherally. Normotenslve rats chd not respond to central mjectlons of Ang II antagonrsts Therefore, It was hypothesized that m the SHR, the hypertension is associated with an overactive brain tissue system. We designed antisense ohgonucleotldes to specifically inhibit Ang II receptors or anglotensmogen to produce longer-lasting effects than a single injection of the pharmacological antagonist The brain was convenient tissue to work on because of the relatively small volumes of oligonucleotides required Antisense inhlbltlon has been developed, particularly m cell culture apphcatlons, to the point where it 1s being tested m climcal totals for HIV and cancer 12~3 The pros and cons of its use have been reviewed elsewhere. 14 Before 1992, however, antisense had not been applied m vlvo with any success. There was much concern about the efficiency of cellular uptake of ohgonucleotldes. As so often happens m science, three or four or more labs simultaneously and independently made and tested antlsense by mJectlons mto the brain. 15-l* In the brain, cellular uptake was not a hmltmg factor The first demonstration of antisense inhibition for hypertension was antisense designed to inhibit angiotensinogen mRNA and Ang to AT,-receptor mRNA in the brain. 19
Designing Antisense Molecules Table 1 lists the characteristics of AS-ODNs that need to be incorporated mto their design and use. The concept of antisense inhibition assumes that a short DNA sequence m the antisense dire&on bmds to the specific mRNA of the target protein in the cytoplasm and prevents either nbosomal assembly or read-through of the message 20 Most AS-ODNs are therefore targeted to the gene initiation codon (AUG) or part of the coding region downstream from it. AntIsense ohgonucleotldes are 15 to 20 bases long, but longer or full-length DNA m the antisense direction 1s used m viral vectors When deslgnmg antisense molecules, one has to consider two antagonistic factors the affimty of ohgonucleotlde to its target sequence, which is dependent on the number and composltlon of complementary bases, and the avadablhty of the target sequence, which 1s dependent on the folding of the mRNA molecule 21
Several reports suggested that AS-ODNs targeted to dlfferent regions of the RNA have unequal efficiencies 22.23 These differences may be related to the predicted secondary structure of the target mRNA 24-26 The folding of the mRNA influences target-sequence avallablhty The RNA double hehces that are responsible for the secondary structure of the mRNA incorporate a weaker G-U base palrmg next to A-U and G-C and are generally short and rarely perfect. Therefore, the design should avold G repeats Burgess and Farrell27 showed that when repeated G sequences appear m the ohgonucleotlde, the effects produced can be due to nonantlsense mechanisms Proper testing of antlsense requires a sense ODN and a mismatch ODN control for every AS-ODN An ODN that has strong (WatsonCrick) base pairmg with 100% complementarmess will form the more thermodynamically favorable structure with its target RNA.28
AS-ODNs have several potential sites of actlon ASODNs inhibit translation by hybndlzmg to the specific mRNA for which they are designed, and the hybndlzatlon prevents either rlbosomal assembly or ribosomal sliding along the mRNA. This hnd of action assumes that ASODNs are acting m the cytosol and do not affect measurable mRNA levels. Indeed, there are several articles reporting antisense effects wlthout detectable change m target mRNA levels 17
Alternatively, the mechamsm can be by reduction of mRNA Decreased mRNA levels can occur by RNase H dlgestlon of the RNA portion of the mRNA-antlsense DNA hybrid RNase H 1s found m the cytoplasm as well as m the nucleus, and it 1s normally mvolved m DNA duphcatlon The role of RNase H 1s to cleave RNA that has bound to DNA Actlvatlon of RNase H IS advantageous because the enzyme leaves the AS-ODN mtact so it is free to hybndlze with another mRNA, making the reactlon catalytic rather than stolchlometrlc. Besides mhlbltlon of translation, other possible antisense mechanisms of action have been proposed Based on studies of cellular uptake of labeled ohgonucleotldes, the picture emerged that most AS-ODNs quickly migrate to the cell nucleus, suggestmg an mtranuclear site of action *9
Antisense DNA can hybridize to its target mRNA or pre-mRNA m the nucleus, forming a partially doublestranded structure that would Inhibit its transport out of the nucleus mto the cytoplasm, thus preventing translation AS-ODNs targeted to mtron-exon Junction sites prevent the sphcmg process and consequently the maturation of the transcript Therefore, antisense molecules might mhlblt pre-RNA splicing or the transport of mRNA from the nu- Currently, the three regions that are considered to be the best targets for designing effective AS-ODNs are the 5' cap region, the AUG translation mltlation codon, and the 3' untranslated region of the mRNA 32-34 Since most mRNAs have an AUG initiator codon site, targeting 12 to 15 of the nelghbormg bases should produce inhibitory ODNs. Routinely, all designed ohgonucleotldes must be checked with the GenBank for exlstmg sequences to avoid any homology with other mRNAs Essentially, antisense design boils down to trial-and-error testing m a model first A general rule suggested by our own experience IS that for a 15-mer ohgonucleotlde, three different sites should be tested with the expectation that at least one will work Obviously, it 1s desirable to have a rapid screening test in vitro or in vlvo for the specific protein that the AS-ODN has been designed to inhibit Controls are sense ODN and mismatch (one or more nucleotldes different from AS) or scrambled, where the entire sequence 1s random
Stability of Oligonucleotides
Ohgonucleotides m their natural form as phosphodlesters are subject to rapid degradation m the blood, mtracellular fluid, or cerebrospinal fluid by exonucleases and endonucleases. The half-life of phosphodlester ohgonucleotides is in the range of minutes m blood and tissue culture media. The half-life of ohgonucleotldes 1s somewhat longer in cerebrospinal fluid, and intact ohgonucleotldes can be detected 24 hours after mJectlon mto the cerebral ventricles.34 Several chemical modifications have been proposed to prolong the half-life of ohgonucleotldes m biological fluids and enhance their uptake while retaining their activity and specificity.
The most widely used modified ohgonucleotldes are phosphorothloates, m which one of the oxygen atoms m the phosphodiester bond between nucleotldes 1s replaced with a sulfur atom These phosphorothloate ohgonucleotides have greater stability m blologlcal fluids than normal ohgonucleotldes. The half-life of a 15mer phosphorothloate ohgonucleotlde 1s 9 hours m human serum, 4 days m tissue culture media,35 and 19 hours m cerebrospmal fluid 36 Phosphorothloate ohgonucleotldes can be synthesized with automated DNA synthesizers, but the product may contain impurities unless purified on an affinity gel. Ohgonucleotldes should be checked to ensure that they are pure.
One or more of the oxygen atoms m the phosphodlester bond can be replaced with a varrety of other compounds, such as methyl groups (methylophosphoriate), alkyl phosphotnester, phosphorarmdate, or boranophosphate, all of which expand the half-life of ohgonucleotides m m vlvo experiments Some clever new designs are being tried in which the ODN has a dumbbell shape produced by a halrpm extension at the 3' end.37 It is hoped that these tid-or fourthgeneration ODNs will provide longer-lasting stability, enhanced uptake kmetics, and affimty for the target 38
Cellular Uptake of Oligonucleotides
To hybridize with the target mRNA, AS-ODNs have to cross the cell membrane Saturable uptake of ohgonucleotides reaches a plateau wlthm 50 hours, occurs rapidly, and depending on the cells, the uptake can be efficient.39 Uptake 1s faster for shorter ohgonucleotldes than for longer ones 39 Decreasing the temperature prevents ohgonucleotide uptake, indicating that there is an active uptake mechanism An 80&D ohgonucleotlde-bmdmg protein has been proposed to be the receptor molecular for ohgonucleotlde uptake.39 An efflux mechanism has also been described indicating temperature-dependent secretion of the oligonucleotldes from the cells to the extracellular space.35
Pharmacology of AS-ODNs
Antisense mhlbltlon can be considered pharmacologltally a drug-receptor interaction m which the ohgonucleotlde is the drug and the target sequence is the receptor. For binding to occur between the two, a minimum level of affinity is required, which 1s provided by hydrogen bonding between the Watson-Crick base pairs and base stacking in the double helix that 1s formed. To achieve pharmacological actlvlty, a minimum number of 12 to 15 bases can provide the mmlmum level of affinity.40 Longer sequences are more specific, but above 20 bases, problems of cell uptake begin to reduce the effectiveness of ODNs
One of the main advantages of antisense mhlbltlon 1s the specificity of the AS-ODN target-sequence interaction provided by the Watson-Crick base paring. An ohgonucleotlde 12 to 15 nucleotides long 1s specific enough statistically to be complementary to a single sequence 13 Increasing the length of the antisense should result m a higher level of specificity, but it decreases its uptake mto cells.39 With viral vectors, however, the uptake problem is overcome because the virus freely enters cells by binding to viral receptors on cell membranes. Therefore, in a viral vector a full-length DNA-antisense sequence can be used The mechanism of action of antisense DNA is different from that of the AS-ODN The antisense DNA produces an antisense mRNA that competes negatively with mRNA in the cytoplasm Toxicity AS-ODNs can inhibit protein synthesis m cultured cells m nanomolar doses The therapeutic window for AS-ODNs is rather narrow?
when testing for the optimal dose, small increments m the high nanomolar range should be tested.34 High concentrations may produce nonspecific binding to cytosollc proteins and give misleading results.
Phosphodiester oligonucleotides are degraded to their naturally occurring nucleotlde bullclmg blocks relatively quickly; therefore, no toxic reaction 1s expected from even high doses of phosphodlester. Studies on phosphorothloated oligonucleotides m rats show that after intravenous injection, phosphorothloated ollgonucleotldes are taken up from the plasma mainly by the liver, fat, and muscle tissues Phosphorothioate oligonucleotldes are excreted through the urine in 3 days, mainly m their orlgmal form. An apparent mild increase m plasma lactate dehydrogenase, and to a lesser extent indicators of a possible transient liver-toxicity, has been noted with very high doses of phosphorothloated ohgonucleotides 41 Whole new classes of oligonucleotlde backbone modifications of phosphorothloate ohgonucleotldes are being developed to avoid the possible liver toxicity m humans. 38.40 The role of candidate genes m the pathogenesis of hypertension can be studied by mhrbmon of the specific, overexpressed target gene with AS-ODNs This approach is being developed m rat models of hypertenston Table 2 lists all the current m viva studies of antisense mhibmon m which blood pressure has been measured The first study on antisense and hypertension was by Gyurko et al,19 who used synthetic AS-ODN, delivered mtracerebroventricularly, m SHR with established hypertension. Based on data mdicatmg an overactive bram RAS is involved m the hypertension of this rat model, we applied antisense mhtbmon to the RAS (Fig 1) We designed an AS-ODN constructed to bases -5 to + 13 of angiotensmogen mRNA (18 mer) and a 15mer ohgonucleotide to bases +63 to +77 of AT,-receptor mRNA 42 The AT,-receptor AS-ODN was phosphorothioated, and the angiotensmogen mRNA AS-ODN was a phosphodiester In both cases, hypertension was significantly reduced by the application of a single dose of 50 pg AS-ODN The mean arterial blood pressure recorded chromcally was reduced by up to 35 mm Hg, m most cases lowering the high blood pressure to normotensive levels These effects were measured 8 and 24 hours after treatment The effects began at 8 hours and were sigmficant at 24 hours The smgle dose of AS-ODN to the AT,-receptor mRNA produced a longlasting, 7-day decrease m blood pressure. AT, receptors were measured to test that the targeted protem had been decreased after this treatment AT,-receptors were sigmfscantly reduced m the paraventrrcular nucleus and rn the anterior thud ventricle area After admnnstration of antisense to angtotensmogen mRNA, brain Ang II levels were sigmficantly reduced (P< OS), mdicatmg mhibition of the brain remn-Ang II synthesis system Blood pressure m these animals also decreased sigmficantly for several days The results indicated that by mhibmng the brain RAS by AS-ODNs to the major substrate or the major receptor, high blood pressure was effectively lowered. Follow-up studies investigated how much decrease there was m the receptor and angiotensmogen levels with these ohgonucleotides and also investigated the other effects of Ang II Ambuhl et al47 quantified the reduction m Ang receptor after AS-ODN against mRNA for the AT, receptor We used autoradiography, quantitative analysis, and membrane bmdmg. Control mlecttons contamed sense or scrambled ohgonucleotides or salme vehicle Three daily mlections of AS-ODN mto the third ventricle of SpragueDawley rats decreased AT,-receptor numbers sigmficantly by 25% m hypothalamic tissue block AT2 receptors were not affected by the AT, antisense Autoradiography showed a decrease m AT,-receptor number m the hypothalamic nuclei and the anterior third ventricle area after the antisense treatment. Since ATI receptors were not reduced, the ATI AS-ODN was shown to be specific In a second series of experiments, smgle mlections of AS-ODN into the lateral ventricles of SHR rats were tested. AS-ODN produced a significant decrease m receptor number m the hypothalamtc area. Sense and scrambled ohgonucleotides did not decrease the receptor numbers srgmficantly The extent of the decrease after mlection of AS-ODN was between 15% and 30%. These relatively modest changes apparently accounted for the physiological effects on hypertension seen by Gyurko et al.19 Wielbo et al48 followed up the mmal finding with a phosphodtester AS-ODN to angiotensmogen mRNA by developmg a phosphorothioated ODN This was admmrstered mtracerebroventricularly m unanesthetized SHR, and blood pressure was recorded The antisense lowered hypertensive blood pressure sigmficantly, while the control sense ODN had no effect The phosphorothroated antisense produced a decrease m blood pressure lasting several days, m contrast to the short l-day effect of phosphorodiesters This undoubtedly reflects the longer-lasting action of the phosphorothioated ODN due to its resistance to nuclease DIrect measurements of angiotensmogen concentration showed that there was a significant decrease m the hypothalamus and also a decrease m the brain stem Again, this supported the concept of centrally mediated regulation of hypertension by an overactive bram Ang system The study also included an experiment using FITC-labeled ohgonucleottde to locate where the cellular uptake of the oligonucleotide occurred Much of tt was close to the site of injection and the surroundmg bram nuclei. This reflects the rapid uptake of ODN by brain cells. No decreases m mRNA were found, and tt was concluded that the angtotensinogen antisense inhibited mRNA translation and not transcription Injections m the brain, however, are obviously not practtcal for hypertension therapy A more practtcal route 1s by oral mtake or injectton mto the peripheral blood. Tomtta et a144 demonstrated a decrease in high blood pressure by AS-ODN against rat angiotensmogen mRNA by dehvermg three antisense ODNs into the portal vein The ODNs were encapsulated m hposomes that contained viral agglutmins The vtral tamer, m this case, was a Sendat virus that had been shown to be efficient m promoting fusion with target cells by Kaneda et al.49 The effect of the ODNs was to produce a transient decrease m plasma angiotensinogen levels m SHR. This decrease m protein was correlated to a decrease m blood pressure and a reduction m hepattc angiotensmogen mRNA Plasma Ang II concentration was also decreased m these rats The reduction m blood pressure, however, was shorter lasting (1 to 4 days) than the reductions m hormone (1 to 7 days) This dtscrepancy has not been explained Recently Wielbo et al,43 m a follow-up study of mjectmg antisense centrally, succeeded m showing a reduction m blood pressure by a smgle intravenous mlection of angiotensmogen ODN encapsulated m a hposome (cholesterol plus phosphohptds) Using an FITC label, they showed that the intravenous route delivered the ODN mostly to the liver. Liver angiotensmogen was reduced after anttsense treatment This study opens the posstbihty of effective direct dehvety through mtravenous inJection with anttsense prepared m a hposome Prehmmary work m a different model of hypertension mdtcates that naked DNA is also effective. Gall1 et a150 injected AS-ODN to angiotensmogen mRNA m 2-kidney, 1 clip rats These rats have high circulating Ang II, which causes the hypertension. The AS-ODN m a single dose (100 pg IV) lowered blood pressure sigmficantly for several (~7) days Anttsense TRH receptor has also been shown to reduce arterial blood pressure m SHR.45 Here, an mtrathecal approach was used to deliver AS-ODN complementary to TRH receptor mRNA The rats were WKY and SHR. The antisense was an 18-base phosphodiester, and the rats received 100 pg per day for 3 days. Twenty-four hours after the last mjection, the magnitude of the response to an intrathecal TRH mjection (10 pg) was significantly reduced m the antisense-treated group In separate experiments, mean resting arterial blood pressure was significantly reduced by the anttsense treatment in SHR but was not affected m WKY. The blood pressure m these rats was relatively low (156k4.8 mm Hg) but was reduced to 119+8 8 mm Hg (Pc.01) No efforts were made to measure a change m the TRH receptors after the treatment in this study. Wtthout showmg that TRH was reduced, one cannot be sure that the antisense has reduced blood pressure by the mechanism of mhibttmg receptor protein synthesis
In another study by the same group, Suzuki et a146 mJetted antisense to c-fos mRNA in the rostra1 ventral medullar of SHR rats, and mean arterial pressure m anesthetized rats was stgmficantly reduced at 6 hours compared with sense-treated controls In this experiment, the protein (c-fos) was shown to be reduced m the brains of the antisense-treated rats In all the studtes on SHR m which WKY normotensive controls have been used, including our own, no effects of anttsense have been found on the WKY This indicates that anttsense is useful for reducing overactive hormonal systems, such as the RAS, but does not interfere with the normal physiologtcal functions of the hormonal system. Several studies report applying AS-ODNs to cell cultures relevant to hypertensive mechanisms. Smooth muscle cell proliferation is a critical feature of many forms of hypertension The oncogene c-myb and the protein myosm are beheved to be mvolved m this process. Simons et al51 used anttsense to nonmuscle myosm heavy chain or c-myb phosphorothtoated ODNs to mhtbit proliferation of smooth muscle cells m vitro. The growth suppression correlated with reducttons m the concentrations of nonmuscle myosm heavy chain and c-myb RNA and their corresponding proteins Sense controls were without effect The effects were long lasting, up to 72 hours. TGF-P IS also tmphcated in the faster growth observed m VSMCs from SHR compared with normotensive controls. AS-ODN complimentary to TGF-P-1 mRNA stgmficantly suppressed VSMC number m SHR but not m WKY Plasmm, an activator of TGF-P, did not stimulate DNA synthesis in the presence of the AS-ODN This cellular study suggests that endogenous TGF-P plays a role m the hypertension of SHR through the increased growth of VSMCs Important pathophysiological events, such as arterial restenosis after balloon catheterizatton, have been effectively Influenced with AS-ODNs Inhibition of two cellcycle regulatory enzymes, cyclm-dependent kinase 2 kmase and cell dtviston cycle 2 kmase, with AS-ODNs resulted m a nearly complete abolition of neomtima formation, which 1s thought to be responstble for arterial restenosis.52 Apphcatton of c-myc AS-ODNs m a pluromc gel to the outside of balloon-catheter-injured blood vessel resulted m a 75% decrease m c-myc expression and significantly reduced neomttma formatton 53 This result also suggests the remarkable penetrating ability of the ohgonucleotides by which they reached the neomtima of the rat carotid from the outside of the vessel The outcome of cerebral mfarctton can be influenced with AS-ODNs. Synthesis of NMDA receptors, which are thought to be responsible for neuronal death after cerebral vascular occlusion, can be inhibited by antisense treatment Such an mhibition reduces the volume of the mfarctton produced experimentally by the occluston of the mtddle cerebral artery. 17
Delivery of Antisense Table 3 shows the currently used methods of dehvermg anttsense for hypertension and some of their advantages and disadvantages.
Naked DNA Direct mjectton of the antisense DNA has been used m the experiments described above.54 For mjecttons into the brain, naked DNA appears to be very successful. In a number of studies usmg different AS-ODNs, there has been efficient uptake and effective reduction m protein and mhibitton of the phystological parameters studied. Uptake is so efficient that one difficulty with mtracerebroventncular mjections is that the DNA tends to be taken up close to the site of mjection and not to spread to other parts of the brain. While this has little impact for hypertension therapy, it is an important consideratton m antisense strategies for Lm and colleagues55 have reported outstanding success with direct gene delivery of human tissue kalhkrein m reducing blood pressure of SHR. They used naked DNA constructs, one with a metallothlomne metal response element, the other with a Rous sarcoma virus 3' LTR promoter. They injected the DNA intravenously. Expression of human kalhkrem was identified m several tissues Blood pressure was significantly reduced for 6 weeks and reached a maximum of -46 mm Hg reduction 54 They have also shown that Intravenous mJectlon of ANP gene as naked ANP reduces hypertension m young SHR (but not m adult SHR) 55 Prelimmary work with a single mtravenous injection of naked AS-ODN directed to anglotensmogen mRNA m the two-kidney, one clip rat reduced renovascular hypertension for several days.50 There was uptake of fluorescent antisense ohgonucleotlde m blood vessels, ludney, and liver However, with this route of admmlstratlon, It 1s difficult to locate where m the body the antisense 1s having Its major effect and whether the effect 1s direct or indirect.
Liposomes
Llposomes, which are self-assembhng particles of blhpld layers, have been used for encapsulating AS-ODN for delivery m blood. Antisense directed to anglotensmogen mRNA m hposomes has had successful results. Wlelbo et a143 compared hposome-encapsulated antisense and naked DNA given intra-arterially They found that only hposome encapsulation was effective, whereas naked DNA was not, under the same condltlons Twenty-four hours after 50 ,ug hposome-encapsulated AS-ODN, blood pressure decreased 25 mm Hg Empty hposomes showed no effect, and hposome-encapsulated scrambled ODN had no significant action Unencapsulated AS-ODN also had no significant effect on blood pressure Confocal mlcrographs of rat liver tissue 1 hour after mtra-arterial mjectlon of 50 1.18 unencapsulated FITC antlsense or hposomeencapsulated FITC-coqugated antisense showed Intense fluorescence m liver tissue smusolds with the hposomeencapsulated ODN Levels of protem (anglotensmogen and Ang II m the plasma) were slgmficantly reduced m the hposome-encapsulated ODN group Antlsense alone, lipids alone, and scrambled ODN m hposomes were wlthout effect on protein levels Llposome development with catlomc lipids allows high transfectlon efficiency of plasmld DNA The short, single-stranded AS-ODNs are not actually encapsulated but are complexed with mlcrolamellar vesicles by electrostatic mteractlons. This simplifies the production of antisense delivery system and allows for a variety of routes of dellvery, mcludmg aerosol nasal sprays and parenteral inJections
Viral Vectors
There are several vu-uses that have been tested for gene dehvery, and each has Its advantages but does not fit perfectly to the descrlptlon of the "ideal viral vector " To be the perfect vector, a virus should fulfill all of the followmg cntena 1 The vector should be safe. This means that It cannot be a virus known to cause disease, or It has to be reenglneered to be harmless The viral vector should not elicit an immune or inflammatory response It should not mtegrate into the genome, randomly carrying the risk of dlsruptmg other cellular genes and mutagenesis The virus also has to be replication-deficient for the prevention of the spread to other tissues or infection of other mdlvlduals An ideal vector would deliver a defined gene copy number into each infected cell Ph&ps Antisense Inhibition and Viral Vector Delivery 183 2. In addmon, the vector must be effictently taken up in target ttssue The virus has to mfect the target cells with high frequency to achieve biological effect.
3. To be practical, the vector should be easy to mampulate and produce m pure form The vtrus should to be able to accommodate the gene of Interest, along with its regulatory sequences, and the recombinant DNA has to be packaged with high efficiency mto the vrral capsid proteins.
Retroviruses
These have been used primarily because of their high efficiency m deltvermg genes to dtvtdmg cells 61 Retrovn-uses permit msertron and stable integration of smglecopy genes Although effective m cell culture systems, they randomly integrate into the genome, which ratuses concerns about then safety for practical use m vrvo Retroviruses can only act m dividing cells, which makes them ideal for tumor therapy but less desrrable where other cells are drvtdmg that need to be protected In hypertenston tesearch, they are being mvestrgated m developmg SHR Researchers at the University of Florida delivered a retrovirus vector (LNSV) containing an antisense DNA to ATn,-receptor mRNA 57 Injections m the heart of 6-weekold SHR resulted m effective long-term mhrbttton of AT,-receptor mRNA and significant mhtbitton of the development of hypertension Several measures indicated that the AT, receptors m vessels were reduced m responsiveness to the treatment.57
Adenoviruses Adenovnus vectors have been tested successfully m then natural host cells, the respiratory endotheha, as well as other tissues such as vascular smooth and striated muscle and bram.62-64 Adenovtrus 1s a double-stranded DNA with 2700 drstmct adenovtral gene products The virus mfects most mammalian cell types because most cells have membrane receptors Vtruses enter the cell by a receptorinduced endocytosis and translocate to the nucleus Most adenovrrus vectors m their current form are eptsomal, that is, they do not integrate mto the host DNA They provide high levels of expression, but the eptsomal DNA will mvariably turn mactrve. In some species, eg, mice, this may be a long time compared with their life span, but m humans it is a hmttatron of the virus as a vector. Repeated mfections result m inflammatory response with consequent ttssue damage. This IS because the adenovrrus expresses genes that lead to immune cell attacks This further hmttation makes current recombinant adenovtrus vectors unsuitable for long-term treatment, and several gene therapy trials using adenovirus have failed to produce acceptable results Prehmmary studies with adenovrrus vectors for delivery of AT,-receptors in mRNA anttsense have been tested m rats and reduce developmg hypertension m SHR.56 The adenovtrus is easy to produce and therefore useful for animal studies of mechanisms However, the adenovrrus as a vector has too many ltmttations at present to be successful m human gene therapy Further engrneermg of the adenovtrus may eventually avoid these limitations.
Adeno-Associated Virus
The AAV has been gaming attention because of its safety and efficiency.65 It has been successfully used for delivering antisense RNA against a-globm66 and HIV LTR,67 and tt 1s our vector of choice for dehvermg anttsense targeted to the AT-l receptor m hypertensive rat models.
AAV 1s a parvovnus, discovered as a contaminatton of adenoviral stocks It IS a ubtqmtous virus (antibodies are present m 85% of the US human population) that has not been linked to any disease. It 1s also classified as a dependovuus, because its rephcation 1s dependent on the presence of a helper VKUS, such as adenovrrus Five serotypes have been isolated, of which AAV-2 1s the best characterized. AAV has a single-stranded linear DNA that 1s encapsidated into capsrd proteins VPl, VP2, and VP3 to form an icosahedral virron of 20 to 24 nm m diameter 65 The AAV DNA 1s approximately 4 7 ktlobases long. It contains two open reading frames and is flanked by two ITRs (Fig 2) There are two major genes m the AAV genome' rep and cap rep codes for proteins responsible for viral replication, whereas cap codes for capsrd protein VPl-3 Each ITR forms a T-shaped haupm structure These terminal repeats are the only essenttal CIS components of the AAV for chromosomal integration Therefore, the AAV can be used as a vector with all viral coding sequences removed and replaced by the cassette of genes for delivery. Three viral promoters have been identified and named p5, p19, and ~40, according to their map position. Transcriptron from p5 and p19 results m production of rep proteins, and transcription from p40 produces the capstd proteins 56 For more powerful expression, we have inserted a CMV promoter Other promoters are being tested that are specific to certain cells, including AVP promoter for cells synthestzmg AVP, neuron-specific enolase, and glial fibnllary acid protein Upon mfectron of a human cell, the wtAAV integrates to the q arm of chromosome 19 68.69 Although chromosoma1 integration requires the terminal repeats, the viral components responsible for sue-specific integration have been recently targeted to the rep proteins 70 With no helper virus present, AAV mfectron remains latent indefinitely Upon supermfechon of the cell with helper virus, the AAV genome 1s excised, replicated, packaged mto vmons, and released to the extracellular fluid. This fact is the basis of rAAV productton for research There are several factors that prompted researchers to study the possibility of usmg rAAV as an expression vector. One is that the requirements for dehvermg a gene to integrate into the host chromosome are surprrsmgly few It 1s necessary to have the 145bp ITRs, which are only 6% of the AAV genome. This leaves room m the vector to assemble a 4 5-kb DNA msertron While this carrying capacity may prevent the AAV from dehvermg large genes, rt is amply suited to dehvermg small genes and antisense cDNA. Capacity 1s sufficient to ensure a specific gene response, a potent promoter, and a marker and/or selector gene, such as a neomycin resistance gene
The second characteristics that makes AAV a good vector candidate is its safety. There is a relatively comphcated rescue mechanism Not only adenovtrus (wild type) but also AAV genes are required to mobrhze the rAAV. The spread of rAAV vectors to nontarget areas can be limited to certain tissues AAV 1s not pathogemc and 1s not associated with disease. The removal of viral coding sequences m producing a +AAV mmtmrzes immune reactions to viral gene expression, and therefore rAAV does not evoke an inflammatory response (in contrast to the recombinant adenovnus) Ilo1 29. AAV is also a good candidate for gene therapy because it has a very broad host range. AAV infects all mammalian tissues tested. with the only exception apparently being vascular endothelial cells." The AAV remains intact for long periods of time.
The limitation of AAV is its production. Although it can be purified and concentrated. which are advantages. it also The result shows that rAAV injected into the brain is taken up by cells and expressed for several weeks.
has to be rendered free of adenolirus. and therefore production is more complicated than for other vectors. The advantages. particularl? its safety. make AAV appear to be one of the best candidates current11 for deli\erq of genes for long-term therapy. Recently!. Flotte and colleagues" haire established gene therap!, phase I trails for cystic fibrosis using AAV gene deliver) in patients Expression of Antisense Sequences With Vectors
The general concept for antisense gene deli\erq in the AAV 1 ector and the steps In\ 01~ ed are shonn m Fig 3. To illustrate these steps. a brief description is given that is applicable to hypertension. Further details are presented in Reference 72.
We constructed plasmids for both AT,-receptor antisense (paAT,) and angiotensmogen anti\ense (paAo) into the AAV-derived expression sector. Initially ne used a plasmid-containing AAV genome and 750 bp DNA inserted into the AAV in the antisense direction downstream from the promoter. The plasmid aas transfected v,ith lipofectamine into NGl OS-15 cells (for the paAT,) or hepatoma H4 cells for the paAo.'q -?-In both cases. there u ere significant reductions in the appropriate proteins. name11 AT, receptor and angiotensmogen. To test that the cells expressed AAV. ue used the re/l gene product as a marker. Immunocytochemical staining R ith a vel~ protein antibody showed that the majority of cells in culture fully expressed the vector. A further development of the AAV baas the insertion of more powerful and specific promoters than the p40 promoter. AAV ivith C&IV promoter and neomycin resistance (r7eo') gene as a selectable marker is noa being used in our current experiments on antisense AT,-receptor mRNA. The AAV cassette contains either full-length DNA in the antisense direction or markers. green fluorescent protein (gfp) gene or /crcZ gene. 6" The NG 108-15 cells with AAV plasmid containmg the 77~0 Uere selected bq antibiotic. G418 (600 pg/mL). and the selected clones viewed for &fp expression. TQO lveeks after transfection. all of the cells \<eere expressing gfil (Fig 1) . There is a latency for AAV integration of 1 to 2 tveeks. then exprecsion increases. Transfection efficiency of this AAV/g$j in different cell lines mcluding ATt20 (mouse pituitary cells). L929 (mouse fibroblastc). HEK239 (human embq omc kidney cells). and NGl08-15 (neoblastoma cells) is over 5O%.'I Expression in vi\0 \\as tested bq direct injection into the brain. An AAV a ith an AVP to drive a 1crrZ gene u as constructed. The \ ector expressed ,&galactosidase in neurons of the paraventricular nucleus and supraoptic nucleus. The expression uas in magnocellular cells. \\hich normally express AVP'Y (Fig 5) . The expression ivas observed at 1 da). 1 \\eek. and 1 month n ith no diminution of signal. This is an example of how AAV can be de\el-oped for specific tissue and/or cell gene expression and sholvs that AAV vectors can deliver foreign genes into adult brain for long periods of tune.
Functional Tests
To prepare the antisense vector. a large fragment of the Ang receptor cDNA (750 bp) \las amplified using PCR and ligated to an A.4V-derived \ ector in the antisense orientation. in place of gfp. The resulting \'ector (rAAV-AS) contained AAV ITRs. a CMV promoter (Ch4Vp). the DNA encoding AT, receptor mRNA m the antisense direction. and a neomycin resistance gene (17eo' To prepare rAAV stocks, recombinant viruses were obtamed usmg HEK293 cells Infected with adenovlrus type 5 and transfected with our antisense vector together with helper plasmld delivering m tram rep and cap genes, necessary for AAV rephcatlon and encapsidatlon 60h9 Because AAV was to be inJected mto animals, it required the CsCl purification procedure, separation from adenovlrus, and heat mactlvation to eliminate any residual adenovlrus
The vector was tested for AT,-receptor mhlbltlon m VItro. Selection of the vector-transfected cells was based on the presence of the neomycin resistance gene. The cells had a significant (P< 01) decrease m Ang II AT, receptor number compared with the control, untransfected cells No effect was seen on the AT;! receptors
To test for effectiveness m vlvo, rAAV-AS plasmld vector was microinfused into the lateral ventricles of adult male SHR Control rats received AAV with gfp reporter gene but without the AS gene ("mock" vector) m vehicle, which was artificial cerebrospmal fluid Blood pressure was measured by the tall-cuff method Thele was a slgmficant decrease m systolic blood pressure m the group of rats that received the rAAV-AS vector No effect was observed m the controls Systolic blood pressure decreased by 23&2 mm Hg m the first week after admnustration This drop m blood pressure was prolonged m 4 rats for 9 weeks, whereas controls had no reduction m blood pressure This was considerably longer than the longest effect observed with antisense ohgonucleotide (Fig 5) This result demonstrates that rAAV-AS m a single application 1s effective m chronically reducing hypertension. Furthermore, intracardiac inJection of rAAV-AS m young SHR (3 weeks old) reduced blood pressure and slowed the development of hypertension T4 The results show the feaulb&y of the rAAV-AS m reducing hypertension They encourage further research on gene regulation m hypertension and exploration of the most effective routes of dehvery applicable to humans Summary Long-term suppression of synthesis of mdivldual proteins 1s desirable m condltlons m which overexpresslon of endogenous genes or expression of foreign genes 15 thought to be the cause of the disease Expression of antlsense vectors produces antisense RNA, which can hybridize with the target mRNA and prevent its translation by either promoting its degradation, preventing Its transport from the nucleus to the cytoplasm, or interfering with rlbosomal function
There are many problems to overcome m the use of antisense technology as a treatment for hypertension that are related to uptake efficiency m various tissues and its stability and activity once inside the cell. However, ASODNs to either AT,-receptor mRNA 01 anglotensmogen mRNA are effective m lowering hypertension m the SHR to normotensive levels A single inJection m the brain or systemically m lipid-encapsulated form 1s effective for up to 7 days. The an&sense approach appears to be working through the expected mechanisms of inhibiting mRNA translation as the appropriate proteins are reduced m correlation to the physiological effect More models of hypertension need to be tested, and the effectiveness of repeated doses to maintain reductions m blood pressure needs study. The long-term goal of prolonged blood pressure control by antisense may he m the delivery of antlsense DNA with viral vectors The case for usmg rAAV as the vector of choice 1s based on safety, slmphclty, and effectiveness The carrying capacity 1s large enough for antlsense cDNA Results with AAV vectors m vitro demonstrate uptake m specific cells (NG108-15) and expression as shown by PCR and RT-PCR Prehmmary results with rAAV-AS produce long-lasting decreases m blood pressure. The blood pressure of adult SHR was reduced significantly for more than 9 weeks by a single mtraventrlcular mjectlon of rAAV-AS In young rats, the development of hypertension was slowed by rAAV-AS We hope these early studies with the AAV vector and hypertension will provide a viable basis for a gene therapy approach to hypertension 
